17 "leukemia" clinical trials found.
-
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
If you or your child have been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL) that has relapsed or is refractory. Relapse means that the cancer has ...
Phase
Match Level: Exact
-
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...
Phase
Match Level: Exact
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The purpose of the study is to determine how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive ...
Phase
Match Level: Exact
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia (AML) ...
Phase
Match Level: Exact
-
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ...
Phase
Match Level: Exact
-
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to previous ...
Phase
Match Level: Exact
-
A PHASE II SINGLE-ARM STUDY OF TOTAL BODY IRRADIATION WITH LINAC BASED VOLUMETRIC MODULATED ARC THERAPY (VMAT) AND IMAGE GUIDED RADIATION THERAPY (IGRT)
The purpose of the study is to determine the safety and efficacy of delivering total body irradiation (TBI) with linac based VMAT technique for patients ...
Phase
Match Level: Exact
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The goal of this trial is to reduce treatmentrelated morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who ...
Phase
Match Level: Exact
-
A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL
The purpose of the study is to optimize the dosage of calaspargase pegol in newly-diagnosed Philadelphia-negative acute lymphoblastic leukemia (ALL) patients based on age. We ...
Phase
Match Level: Exact
-
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability at ...
Phase
Match Level: Exact
